Related references
Note: Only part of the references are listed.KRT17 as a prognostic biomarker for stage II colorectal cancer
Daisuke Ujiie et al.
CARCINOGENESIS (2020)
EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions
Sho Sasaki et al.
GASTRIC CANCER (2019)
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
Takeshi Fukumoto et al.
CANCER RESEARCH (2019)
Prognostic role of ARID1A negative expression in gastric cancer
Mai Ashizawa et al.
SCIENTIFIC REPORTS (2019)
ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion
Mike R. Wilson et al.
NATURE COMMUNICATIONS (2019)
Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer
Young-Bae Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Targeted and novel therapy in advanced gastric cancer
Julie H. Selim et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
Takeshi Fukumoto et al.
CELL REPORTS (2018)
Targeted therapy according to next generation sequencing-based panel sequencing
Motonobu Saito et al.
FUKUSHIMA JOURNAL OF MEDICAL SCIENCE (2018)
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Julie George et al.
CLINICAL CANCER RESEARCH (2017)
Estimation of lifetime cumulative incidence and mortality risk of gastric cancer
Yukari Taniyama et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
ARID1A-mutated ovarian cancers depend on HDAC6 activity
Benjamin G. Bitler et al.
NATURE CELL BIOLOGY (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells
Tianfu Yu et al.
ONCOTARGET (2017)
Stomach cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study
Melissa A. Jim et al.
CANCER (2017)
Targeting EZH2 in cancer
Kimberly H. Kim et al.
NATURE MEDICINE (2016)
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Chris T. Williamson et al.
NATURE COMMUNICATIONS (2016)
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kimberly H. Kim et al.
NATURE MEDICINE (2015)
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Benjamin G. Bitler et al.
NATURE MEDICINE (2015)
Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations
Hiroyuki Abe et al.
PATHOBIOLOGY (2015)
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Jianfeng Shen et al.
CANCER DISCOVERY (2015)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
ARID1B is a specific vulnerability in ARID1A-mutant cancers
Katherine C. Helming et al.
NATURE MEDICINE (2014)
OpenCFU, a New Free and Open-Source Software to Count Cell Colonies and Other Circular Objects
Quentin Geissmann
PLOS ONE (2013)
ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?
Jennifer N. Wu et al.
CANCER DISCOVERY (2013)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Sarah K. Knutson et al.
NATURE CHEMICAL BIOLOGY (2012)
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Wei Qi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
Kai Wang et al.
NATURE GENETICS (2011)
Share Paper
